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Introduction
In 1997, when I reported on the progress of the “osteo-
porosis revolution,”
1 ﬁ  ve topics were emphasized: 
genetics, local factors, bone mass measurements, bio-
chemical markers, and prevention and therapy. During 
the past 10 years there has been substantial progress in 
all of these areas, but the revolution is by no means 
over. This review summarizes our current concepts of 
epidemiology, pathogenesis, diagnosis, prevention, and 
treatment with an emphasis on the advances that have 
been made during the past decade.
The osteoporosis revolution is a relatively recent 
problem in human history, due largely to the great 
increase in life expectancy and the effects of “civiliza-
tion,” that is, the movement of humans from outdoors 
to indoors and from heavy physical activity to sedentary 
occupations. Although originally the diagnosis of osteo-
porosis was made after patients had had a fragility frac-
ture, we now can make a diagnosis of osteoporosis 
before fractures occur when there is a marked reduction 
of bone mineral density (BMD) or of osteopenia, when 
there is a moderate reduction in BMD. This has made 
it possible to start preventive measures and early therapy 
in high-risk patients before there is any fracture. Nev-
ertheless, most patients are not diagnosed until after 
their ﬁ  rst fragility fracture; and, unfortunately, many 
are not diagnosed or treated even after that fracture. 
Although the highest incidence is among postmeno-
pausal women, substantial numbers of older men are 
affected; and a few younger individuals, particularly 
those with important secondary causes for bone loss, 
are also at risk for fragility fractures.
Epidemiology
Osteoporosis is a common disorder. There were approx-
imately 2 million fragility fractures in the United States 
in 2005, and this number will increase to 3 million by 
2025 unless we institute more effective preventive mea-
sures.
2  Similar ﬁ  gures have been reported for most 
developed countries.
3 In the United States, about half 
of these fractures occur in patients with a sufﬁ  ciently 
low bone mass to warrant the diagnosis of osteoporosis 
(i.e., more than 2.5 SD below the young adult mean), 
and the other half occur in patients with osteopenia 
(i.e., BMD of −1.0 to 2.5 SD). The most common fragil-
ity fractures are of the proximal femur, lower thoracic 
and lumbar vertebrae, and distal radius. However, fra-
gility fractures can occur in many other sites. Although 
the absolute incidence of fragility fractures is increasing 
rapidly, largely because of greater longevity, a number 
of studies have suggested that age-speciﬁ  c rates are 
decreasing in some countries, perhaps due to greater 
recognition of the problem and greater attention to 
bone health. The U.S. Surgeon General made this the 
subject of a major report on “Bone Health and Osteo-
porosis.”
4 The World Health Organization, which estab-
lished the present diagnostic criteria, is making a major 
effort to redeﬁ  ne osteoporosis in terms of absolute frac-
ture risk and establish better approaches to diagnosis 
and prevention.
Pathogenesis
Our basic concepts of the pathogenesis of osteoporosis 
have not changed greatly during the last decade, but 
some new pathways have been identiﬁ  ed.
5  The four 
basic mechanisms are (1) failure to achieve optimal 
peak bone mass and strength during growth and devel-
opment. This is largely determined by genetics but 
is also contributed to by nutrition and lifestyle. (2) 
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Increased bone resorption with aging, particularly after 
menopause. This is largely due to estrogen deﬁ  ciency 
but may be enhanced by calcium and vitamin deﬁ  ciency 
producing secondary hyperparathyroidism. An increase 
in inﬂ  ammatory cytokines may play a role. (3) Inade-
quate bone formation during remodeling. This is prob-
ably due to age-related impairment of osteoblastic cell 
renewal and function and to changes in speciﬁ  c growth 
factors. (4) Increased propensity to fall. This occurs 
because of neural and muscular impairment with aging 
as well as the increasing number of drugs given to the 
elderly for other disorders that can impair balance or 
perception.
Genetics
There have been remarkable advances in our under-
standing of the genetic determinants of bone mass and 
strength.
6–8 Perhaps the most important has been iden-
tiﬁ  cation of the Wnt signaling pathway.
9 Activation of 
Wnt signaling in bone results in increased bone forma-
tion and probably in decreased resorption. The pathway 
also has an effect on early precursor cells to direct them 
to the osteoblastic lineage rather than to adipocytes 
or cartilage cells. Activating mutations of lipoprotein-
related receptor-5 (LRP-5), which is part of the recep-
tor complex for Wnt ligands, produce a high bone mass 
phenotype.
9–11 Deletion of LRP5 produces severe osteo-
porosis.
12  A high bone mass phenotype also occurs 
when inhibitors of this pathway, sclerostin or dickkopf 
(DKK),
13 are deleted. The potential role of polymor-
phisms in the multiple proteins involved in this complex 
regulatory system are just beginning to be explored and 
could account for genetic differences in bone mass and 
strength.
Other ﬁ  ndings point to a possible role of abnormali-
ties of collagen in osteoporosis, particularly polymor-
phisms of the α1 collagen gene, which are associated 
with increased skeletal fragility.
14 This and other ﬁ  nd-
ings call into question the concept that there are no 
biochemical abnormalities of the matrix in osteoporo-
sis. Subtle abnormalities may indeed exist and contrib-
ute to fragility. Many other candidate genes have been 
analyzed, all of which appear to contribute relatively 
small effects on bone mass and fragility but which in 
combination could be important determinants of frac-
ture risk as well as the response to therapy.
15 Moreover, 
interactions between genetics and environment may 
modify these effects.
16
Nutrition and lifestyle
Our hunter-gatherer and agricultural ancestors proba-
bly had stronger bones. This could be due not only to a 
direct effect of physical activity but to greater nutrient 
intake, particularly of calcium, associated with this 
activity, as well as greater sun exposure and hence 
higher levels of vitamin D.
17 These factors may be of 
particular importance during childhood and adoles-
cence, when peak bone mass is developed. Many studies 
indicate that gains in bone mass can be achieved by 
improving physical activity and nutrition, but most also 
show that these gains are lost when the program is 
discontinued.
18 In addition to calcium and vitamin D, 
protein intake and vitamin K may be critical for achiev-
ing bone mass and strength.
19 Other nutritional inter-
ventions have been explored, such as changes in the 
proportion of saturated and unsaturated fats or in 
omega-3 fatty acids, but the data are limited.
20,21
Accelerated bone resorption
Although it is clear that estrogen deﬁ  ciency results in 
accelerated bone resorption at any age, the precise 
mechanisms have still not been established.
5 Moreover, 
there may be separate effects of androgens and other 
hormones involved in gonadal regulation such as 
follicle-stimulating hormone (FSH) or inhibin.
22–24 
Recent studies indicate that estrogen may act at multi-
ple sites — on both the hematopoietic precursors of the 
osteoclasts and the osteoblast-osteoclast interaction 
that regulates bone resorption. Thus, estrogen adminis-
tration can decrease bone resorption by decreasing the 
ability of marrow cells to respond to stimulation by 
receptor activator of NFκB (RANKL) and by decreas-
ing the expression of RANKL in marrow cells.
25,26 
We are still not sure whether the RANKL-expressing 
cells that are affected by estrogen are entirely from 
the osteoblast lineage or include members of the lym-
phocyte family. In any event, the production of bone-
resorbing cytokines may mediate this response.
27–31 Of 
great interest is the observation that the amount of 
estrogen required to affect bone in postmenopausal 
women may be substantially less than that required to 
affect the classic target organs, such as the breast or 
uterus, although this may not be the case in rodents.
32,33 
Fracture risk is highest in both men and women with 
the lowest estrogen levels, and doses of estrogen that 
are one-quarter or less of the usual doses that are given 
at menopause can prevent bone loss. Because of the 
recent data indicating that with higher doses of estrogen 
the costs may outweigh the beneﬁ  ts, the exploration of 
ultra-low-dose estrogen for prevention and treatment 
of osteoporosis is quite attractive. Large studies are 
required to be determine if these low doses actually do 
have less risk and are effective in reducing fractures.
Low intake of calcium and low levels of vitamin D are 
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porosis.
34 These conditions aggravate bone loss by pro-
ducing secondary hyperparathyroidism and increased 
bone resorption; and they may also have adverse effects 
on muscle strength and physical performance and thus 
increase the risk of falls.
35,36 Recent studies have sug-
gested that vitamin D requirements for optimal health 
may be much higher than the usually recommended 
levels. Because the sun does not activate vitamin D for-
mation in the skin in northern latitudes during the winter, 
supplementation is important. Moreover vitamin D 
insufﬁ  ciency is still quite common in equatorial regions, 
probably because the individuals cover themselves and 
avoid sun exposure. There is still debate concerning the 
optimal levels of vitamin D, but a daily intake of 2000 U 
or even more appears to be quite safe.
17,36
Inadequate bone formation
During childhood and adolescence the skeleton main-
tains remarkably high rates of bone formation for the 
modeling of new bone and for remodeling. Thus, rates 
of bone resorption much higher than those encountered 
in patients with osteoporosis can occur in the presence 
of substantial bone gain. At some point shortly after 
peak bone mass has been achieved, this capacity for 
high rates of bone formation diminishes and the amount 
of new bone in remodeling sites on the trabecular bone 
surfaces (mean wall thickness) progressively decreases.
37 
Trabecular bone and, to a lesser extent, cortical bone 
mass probably begin to decrease at some sites when 
people are in their twenties, long before the major hor-
monal changes of menopause or aging.
38 However, sex 
hormones may still play a role in the changes in bone 
of younger individuals.
39,40
The reasons for the age-related decrease in bone for-
mation are not well understood. It is possible that after 
multiple replications the precursor cells of the osteo-
blastic lineage gradually lose their capacity to replicate 
and differentiate. The changes in bone mass during this 
period are extremely variable, and it is also possible that 
individuals destined to become osteoporotic are the 
ones who show the greatest impairment of bone forma-
tion as younger adults.
41,42 This may be due to changes 
in growth factors. Many growth factors affect the skel-
eton, including insulin-like growth factor-1, ﬁ  broblast 
growth factor, vascular endothelial growth factor, bone 
morphogenetic proteins (BMPs), transforming growth 
factor-β, and prostaglandins.
43–48  Moreover, cytokines 
can inhibit formation as well as stimulate resorption.
49 
Polymorphisms in the genes for some of these factors 
have been implicated as determinants of bone mass and 
fracture risk.
50,51
The role of the Wnt signaling pathway in the patho-
genesis of osteoporosis has not yet been fully deﬁ  ned.
52 
The clinical ﬁ  ndings of increased bone mass due largely 
to increased bone formation in patients with increased 
activity of this pathway as well as the ﬁ  nding of severe 
osteoporosis in the LRP-5-deﬁ  cient osteoporosis pseu-
doglioma syndrome, make it reasonable to look for 
smaller variations in Wnt signaling as a mechanism for 
impaired bone formation in osteoporosis. The regula-
tion of this pathway is complex, and there are many sites 
at which abnormalities could occur, including not only 
the inhibitory proteins such as sclerostin, secreted friz-
zled related protein, and dickkopf but also Wnt ligands 
and the LRP-5 and frizzled receptors themselves.
53,54 
Polymorphisms of LRP-5 have been associated with 
differences in bone mass and fracture incidence.
55 More-
over, mutations in LRP-5 have been described in 
children with primary osteoporosis.
56 This possibility is 
reinforced by the observation that the most effective 
current anabolic agent, intermittent PTH, appears to 
act at least in part by reducing sclerostin, presumably 
leading to activation of Wnt signaling.
11,57–59 One feature 
of the Wnt pathway that is of particular interest is the 
observation that not only does activation increase bone 
formation, it may also decrease bone resorption and 
decrease the propensity for precursor cells to differenti-
ate into adipocytes.
Another exciting new area that may be relevant to 
the pathogenesis of osteoporosis is the evidence that 
bone formation is under neural control. Effects of leptin 
mediated by the central nervous system and peripheral 
effects of both the β-adrenergic and the cannabinoid 
systems have been implicated in regulation of the skel-
eton.
60–62  Moreover, an effect of β-blockers on bone 
density and fractures has been reported, although the 
results are not entirely consistent.
63
Diagnosis of osteoporosis and assessment of 
fracture risk
Although the use of BMD for diagnosing osteoporosis 
has been broadly applied during the last two decades, a 
new approach in which BMD and other risk factors are 
used together to estimate true absolute fracture risk is 
rapidly being developed and likely to replace the use 
of BMD alone, with its arbitrary diagnostic cutoffs.
64 
Currently, the factors that are most frequently used to 
assess fracture risk are age, family and personal fracture 
history, body weight, and the presence of aggravating 
disorders such as rheumatoid arthritis. The use of bio-
chemical markers of bone turnover to reﬁ  ne this assess-
ment has not yet become established, even though there 
is good evidence that high turnover is associated with 
increased fracture risk.
65 One reason for the uncertainty 
concerning the use of biochemical markers is the lack 
of uniformity in their assay measurements.
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An important advance that is under development, but 
likely to be widely available in the next decade, is assess-
ment of the microarchitecture of the skeleton. It is now 
possible to assess trabecular structure and measure such 
important properties as trabecular spacing and the rela-
tive proportion of rods and plates using either high-
resolution computed tomography (CT) or magnetic 
resonance imaging (MRI), but these procedures are still 
not at the stage of general clinical application.
67,68
One critical aspect of diagnosis is the appropriate 
workup to rule out important secondary causes of bone 
loss and fragility.
69 A number of cost-effective stepwise 
approaches have been described, but they are not being 
applied in most cases.
Genetic diagnosis, except for the severe forms of 
skeletal fragility that we term osteogenesis imperfecta, 
is not yet a clinically useful option. However, it seems 
likely that in the future, when a substantial number of 
genetic polymorphisms that impinge on bone mass and 
strength have been identiﬁ  ed, a genetic proﬁ  le could be 
developed that would greatly enhance the assessment 
of fracture risk.
Prevention and treatment
There have been substantial advances in the orthopedic 
management of fragility fractures that have reduced 
morbidity and mortality and shortened the time to 
recovery, but they are beyond the scope of this review. 
The concept of fracture prevention is central to medical 
treatment of osteoporosis. The goal of treatment is to 
reduce fracture risk (i.e., prevent future fractures). 
There has been increasing emphasis on a lifelong 
approach to this goal.
4 Improved bone health in chil-
dren, particularly in adolescents during the rapid growth 
spurt, through better nutrition and exercise might have 
a substantial effect on the risk of fractures later in life. 
These same bone health measures are critical for any 
therapeutic program in older individuals who have 
moderate to severe bone loss. In many of these patients, 
however, pharmacotherapy is also indicated. Ten years 
ago the most widely used agents were estrogens; but 
with the evidence from the Women’s Health Initiative 
that the risks of estrogen in terms of cardiovascular 
disease and breast cancer might outweigh the beneﬁ  ts, 
this use has decreased.
70 Hence, bisphosphonate therapy 
has become the preferred approach.
71,72
Large clinical trials have demonstrated the antifrac-
ture efﬁ  cacy of bisphosphonates, but they are far from 
ideal drugs. When given orally only 1% or less of the 
dose is absorbed, and variations of this absorption are 
likely to alter efﬁ  cacy. There are also side effects, par-
ticularly with oral administration, that limit their use; 
furthermore, fracture reduction averages only about 
50%. Intravenous bisphosphonates are being devel-
oped. For zoledronic acid, there is recent evidence of 
substantial antifracture efﬁ  cacy when given as a single 
infusion once a year for 3 years.
73  One concern is 
that we still do not know the long-term safety of 
bisphosphonates.
74
During the past decade there has also been increasing 
use of a selective estrogen receptor modulator (SERM), 
raloxifene.
72 Efﬁ  cacy has been demonstrated, but only 
for vertebral fractures. Newer SERMs are being tested 
and may show greater clinical efﬁ  cacy. Another 
approach that deserves further exploration is the use of 
ultra-low-dose estrogen. This might avoid the adverse 
effects of therapy and has been shown to increase bone 
density, but it has not yet been tested for fracture 
efﬁ  cacy.
75,76
Calcitonin is an antiresorptive agent, but its efﬁ  cacy 
in the treatment of osteoporosis remains uncertain.
71,72,77 
A number of other antiresorptives are currently under 
study.
78 They include the use of an antibody to RANKL, 
which blocks its interaction with RANK and rapidly 
reduces bone resorption. Injections of this antibody 
can maintain decreased resorption rates for 6 months 
and increase BMD as effectively as bisphosphonates.
79 
Direct inhibition of osteoclast activity by blocking acid 
secretion, inhibiting cathepsin K, or interfering with the 
adhesion of osteoclasts via integrin receptors are also 
being explored.
80–82
The relative effects of antiresorptive therapy are 
similar in patients with mild or severe osteoporosis; in 
the latter, the fracture rate of remains quite high, so 
many patients might be regarded as therapeutic failures. 
In addition some patients continue to lose BMD on 
antiresorptive therapy. As yet, there is no evidence that 
changing from one antiresorptive to another has any 
beneﬁ  t, although intravenous therapy might be consid-
ered in patients who do not absorb or do not tolerate 
oral bisphosphonates. It is in these patients that ana-
bolic therapy is most often considered.
Anabolic therapy
That low doses of parathyroid hormone given intermit-
tently could increase bone mass was demonstrated in 
experimental animals more than half a century ago. 
However, the clinical application of this effect was 
achieved only in the last decade.
83,84 Daily subcutaneous 
administration of synthetic 1–34 parathyroid hormone 
(teriparatide) was found to increase bone density and 
reduce fracture risk, not by inhibiting resorption but 
by stimulating both resorption and formation, with a 
greater formation effect, thus resulting in increased 
bone mass. This may be related to decreased sclerostin 
or increased insulin-like growth factor-2 production.
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The new bone formed is structurally sound, in contrast 
to the earlier studies using sodium ﬂ  uoride, which 
increased bone mass but also increased fragility at 
higher doses.
86 Teriparatide has been shown to be effec-
tive in both men and women and in patients with glu-
cocorticoid-induced osteoporosis. One concern has 
been that its initial efﬁ  cacy may be reduced in patients 
who are treated with bisphosphonates.
87  However, 
teriparatide still increases bone density in such 
patients.
88
Although teriparatide is effective, its use has been 
limited by the inconvenience of daily injection as well 
as the high cost. Alternatives to injection of teriparatide 
are being explored, including administration by nasal 
spray
89 or the use of “calcilytic” agents that interfere 
with the calcium receptor and produce a transient 
increase in endogenous parathyroid hormone (PTH) 
secretion.
90 Prostaglandins have been shown to increase 
both bone resorption and formation with a net increase 
in bone mass in animals.
91 Selective agonists for prosta-
glandin receptors are being explored for the therapy of 
local skeletal defects,
92  but their multiple effects on 
other organ systems may limit their use as skeletal ana-
bolic agents.
Agents that inhibit resorption and stimulate formation
Most recently, strontium ranelate has been developed 
as an agent that is reported to inhibit bone resorption 
and stimulate bone formation. Its effects on bone mass 
are difﬁ  cult to evaluate because strontium is incorpo-
rated into the mineral and alters its density. However, 
strontium ranelate has been shown to reduce fractures.
93 
An exciting new approach to the possible simultaneous 
inhibition of resorption and stimulation of formation 
would be activation of the Wnt signaling pathway. An 
approach that is currently being explored is “disinhibi-
tion” of Wnt signaling, which can be achieved by anti-
bodies to sclerostin.
94
Future direction
In view of the remarkable and unexpected ﬁ  ndings of 
the last decade, it is hazardous to predict where the next 
decade will lead. Many more factors that regulate bone 
remodeling and inﬂ  uence skeletal integrity are being 
discovered, and studies of these factors should lead 
to better understanding of the pathogenesis and new 
approaches to therapy. An equally critical goal is to 
improve the application of what we already know to 
reversing the ever-increasing burden of osteoporotic 
fractures worldwide. This will require political and 
socioeconomic changes as well as improvements in the 
distribution of medical care. Orthopedists can play an 
important role here — for example, developing pro-
grams that ensure that patients with fragility fractures 
are followed up with appropriate diagnosis and treat-
ment and supporting and promoting efforts to improve 
bone health at all ages.
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